Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved a generic lenalidomide product for Teva under ANDA201452, expanding access to lenalidomide formulations.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Alvogen, Inc.)
FDA approved Alvogen, Inc.'s original Abbreviated New Drug Application for a generic lenalidomide product (ANDA 210480).
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (EXELAN PHARMACEUTICALS INC.)
FDA approves a generic lenalidomide product from Exelan Pharmaceuticals under an original application. The drug is indicated for several hem…
-
CLINICAL_TRIALS trial_result · 2023-02-16Clinical Trial Update: Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating Umbilical Cord Blood NK cells with Rituximab, high-dose chemotherapy, and stem cell transplant in recurrent or refr…
-
CLINICAL_TRIALS trial_result · 2023-02-09Clinical Trial Update: Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma [Phase 1]
Phase I trial evaluating a combination of Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab in indolent B-cell lymphoma…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-02-08FDA Approved: LENALIDOMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical Industries' Lenalidomide Original Application, granting a generic lenalidomide product for multiple myeloma …
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating chemotherapy plus vaccination for mantle cell lymphoma has completed; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-01-20Clinical Trial Update: Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant [Phase 2]
Phase 2 trial evaluating ibrutinib in patients with refractory or relapsed lymphoma after donor stem cell transplant completed; results post…
-
FDA approval · 2023-01-19FDA Approved: BRUKINSA — Supplemental Application (BeOne Medicines USA, Inc.)
FDA approved a supplemental application for BRUKINSA (zanubrutinib) submitted by BeOne Medicines USA, Inc.
-
CLINICAL_TRIALS trial_result · 2022-12-14Clinical Trial Update: A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 study evaluating copanlisib combined with ibrutinib in mantle cell lymphoma has completed with posted results.
-
FDA approval · 2022-12-07FDA Approved: VIVIMUSTA — Original Application (Azurity Pharmaceuticals, Inc.)
FDA approved VIVIMUSTA (bendamustine hydrochloride) from Azurity Pharmaceuticals under Original Application NDA212209.
-
FDA approval · 2022-12-07FDA Approved: BENDAMUSTINE HYDROCHLORIDE — Original Application (Apotex Corp)
FDA approved bendamustine hydrochloride via Apotex Corp's original application, indicating the approval of a Bendamustine HCl product.
-
CLINICAL_TRIALS trial_result · 2022-10-24Clinical Trial Update: Ublituximab + Ibrutinib in Select B-cell Malignancies [Phase 1, Phase 2]
A phase 1/2 trial evaluating ublituximab in combination with ibrutinib for select B-cell malignancies has completed.
-
FDA approval · 2022-10-11FDA Approved: BORTEZOMIB — Original Application (Somerset Therapeutics LLC)
FDA approved a generic version of Bortezomib under an Original Application (ANDA 211898) for Somerset Therapeutics LLC. The product is used …
-
CLINICAL_TRIALS trial_result · 2022-09-15Clinical Trial Update: Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL [Phase 2]
Phase 2 trial evaluating carfilzomib with lenalidomide and dexamethasone for mantle cell lymphoma that relapsed after or is intolerant to BT…
-
CLINICAL_TRIALS trial_result · 2022-09-13Clinical Trial Update: Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL [Phase 2]
Phase 2 study of AT13387 (Onalespib) in ALK+ anaplastic large cell lymphoma, mantle cell lymphoma, and BCL-6+ diffuse large B-cell lymphoma …
-
FDA approval · 2022-09-06FDA Approved: LENALIDOMIDE — Original Application (EXELAN PHARMACEUTICALS INC.)
The FDA approved Exelan Pharmaceuticals Inc.'s original application for lenalidomide, granting approval of a generic version of the cancer d…
-
CLINICAL_TRIALS trial_result · 2022-08-31Clinical Trial Update: Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies [Phase 1]
Phase 1 trial update of a genetically modified T-cell therapy targeting ROR1 in advanced malignancies, with terminated status and posted res…
-
FDA approval · 2022-08-31FDA Approved: LENALIDOMIDE — Original Application (Alvogen, Inc.)
FDA approved the original application for Lenalidomide from Alvogen, Inc., enabling a generic version of lenalidomide to enter the market.
-
FDA approval · 2022-08-30FDA Approved: LENALIDOMIDE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved lenalidomide as an original application for Mylan Pharmaceuticals Inc., establishing a generic version of lenalidomide.
-
FDA approval · 2022-08-24FDA Approved: IMBRUVICA — Original Application (Pharmacyclics LLC)
The FDA approved the original application for IMBRUVICA (ibrutinib) from Pharmacyclics LLC, establishing its initial approval for mantle cel…
-
FDA approval · 2022-08-24FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
The FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
CLINICAL_TRIALS trial_result · 2022-08-17Clinical Trial Update: Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 trial update for Zanubrutinib combined with rituximab in patients with newly diagnosed untreated mantle cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-08-09Clinical Trial Update: Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL [Phase 2]
Phase II study evaluating age-adjusted rituximab, bendamustine, and cytarabine as induction therapy in older patients with mantle cell lymph…
-
FDA approval · 2022-08-03FDA Approved: CALQUENCE — Original Application (AstraZeneca Pharmaceuticals LP)
FDA approves CALQUENCE (acalabrutinib) from AstraZeneca in an original application for mantle cell lymphoma.